{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:48:42Z","timestamp":1792702122028,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1183323"],"award-info":[{"award-number":["APP1183323"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2008450"],"award-info":[{"award-number":["2008450"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","bmn.com","clinicalkey.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.tips.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T08:43:29Z","timestamp":1725957809000},"page":"892-903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":351,"title":["Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-7382","authenticated-orcid":false,"given":"Phurpa","family":"Wangchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karma","family":"Yeshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Loukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2024.08.003_bb0005","doi-asserted-by":"crossref","first-page":"21116","DOI":"10.1021\/acsnano.3c04819","article-title":"An orally-administered nanotherapeutics with carbon monoxide supplying for inflammatory bowel disease therapy by scavenging oxidative stress and restoring gut immune homeostasis","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.tips.2024.08.003_bb0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2024.08.003_bb0015","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses","volume":"21","author":"Buie","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0020","doi-asserted-by":"crossref","first-page":"36061","DOI":"10.1021\/acsami.3c09342","article-title":"Oral nanotherapeutics of andrographolide\/carbon monoxide donor for synergistically anti-inflammatory and pro-resolving treatment of ulcerative colitis","volume":"15","author":"Zhou","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.tips.2024.08.003_bb0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jconrel.2024.04.016","article-title":"The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome","volume":"369","author":"McCoubrey","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tips.2024.08.003_bb0030","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune system","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2024.08.003_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111448","article-title":"The role of fatty acids in Crohn\u2019s disease pathophysiology \u2013 an overview","volume":"538","author":"Piotrowska","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tips.2024.08.003_bb0040","first-page":"1653","article-title":"Validation of rapid fecal calprotectin assay using particle enhanced turbidimetric immunoassay for inflammatory bowel disease","volume":"14","author":"Oka","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.tips.2024.08.003_bb0045","article-title":"C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis","volume":"11","author":"Ishida","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.tips.2024.08.003_bb0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","article-title":"Approach to the management of recently diagnosed inflammatory bowel disease patients: a user\u2019s guide for adult and pediatric gastroenterologists","volume":"161","author":"Agrawal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2024.08.003_bb0055","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2024.08.003_bb0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/ecco-jcc\/jjac152","article-title":"Application of deep learning models to improve ulcerative colitis endoscopic disease activity scoring under multiple scoring systems","volume":"17","author":"Byrne","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0065","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/gutjnl-2021-326376","article-title":"PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system","volume":"71","author":"Gui","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.tips.2024.08.003_bb0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gie.2022.08.023","article-title":"Endocytoscopy for assessing histologic inflammation in ulcerative colitis: development and prospective validation of the ELECT (ErLangen Endocytoscopy in ColiTis) score (with videos)","volume":"97","author":"Vitali","year":"2023","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.tips.2024.08.003_bb0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.gastro.2023.09.049","article-title":"Using computer vision to improve endoscopic disease quantification in therapeutic clinical trials of ulcerative colitis","volume":"166","author":"Stidham","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2024.08.003_bb0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gie.2022.02.012","article-title":"Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis using multiple endoscopic platforms: a prospective multicenter international study (with video)","volume":"96","author":"Cannatelli","year":"2022","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.tips.2024.08.003_bb0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/1751-2980.13126","article-title":"External validation of the Paddington International Virtual Electronic ChromoendoScopy ScOre as a good endoscopic score to define mucosal healing and predict long-term clinical outcomes in ulcerative colitis","volume":"23","author":"Ruan","year":"2022","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.tips.2024.08.003_bb0090","article-title":"Today and tomorrow: the use of biomarkers in inflammatory bowel disease","volume":"1","author":"Rowan","year":"2023","journal-title":"Can IBD Today"},{"key":"10.1016\/j.tips.2024.08.003_bb0095","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","article-title":"Large-scale plasma proteomics comparisons through genetics and disease associations","volume":"622","author":"Eldjarn","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tips.2024.08.003_bb0100","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.3390\/ijms24119386","article-title":"A current state of proteomics in adult and pediatric inflammatory bowel diseases: a systematic search and review","volume":"24","author":"Fabian","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2024.08.003_bb0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5005\/jp-journals-10018-1411","article-title":"Comparison of fecal calprotectin with different endoscopic scores in the assessment of ulcerative colitis (UC) activity and its utility in differentiating IBS from IBD","volume":"13","author":"Acharya","year":"2023","journal-title":"Euroasian J. Hepatogastroenterol."},{"key":"10.1016\/j.tips.2024.08.003_bb0110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.dld.2023.09.018","article-title":"Histologic findings at diagnosis as predictive markers of clinical outcome in pediatric ulcerative colitis","volume":"56","author":"Catassi","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.tips.2024.08.003_bb0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.gastha.2021.10.006","article-title":"Fecal leukocyte esterase, an alternative biomarker to fecal calprotectin in inflammatory bowel disease: a pilot series","volume":"1","author":"Trasolini","year":"2022","journal-title":"Gastro Hep Adv."},{"key":"10.1016\/j.tips.2024.08.003_bb0120","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1038\/s41467-021-24235-0","article-title":"Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen","volume":"12","author":"Soomro","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2024.08.003_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2022.100487","article-title":"Resistin, elastase, and lactoferrin as potential plasma biomarkers of pediatric inflammatory bowel disease based on comprehensive proteomic screens","volume":"22","author":"Louis Sam Titus","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.tips.2024.08.003_bb0130","first-page":"6690","article-title":"Serum biomarkers confirming stable remission in inflammatory bowel disease","volume":"11","author":"Kessel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.tips.2024.08.003_bb0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000527846","article-title":"Positioning and usefulness of biomarkers in inflammatory bowel disease","volume":"104","author":"Sakurai","year":"2022","journal-title":"Digestion"},{"key":"10.1016\/j.tips.2024.08.003_bb0140","article-title":"Usefulness of the optimal cutoff value and delta value of leucine-rich alpha 2 glycoprotein in ulcerative colitis","volume":"4","author":"Matsumoto","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.tips.2024.08.003_bb0145","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.3390\/jcm11216366","article-title":"Serum leucine-rich \u03b12 glycoprotein: a biomarker for predicting the presence of ulcerative colitis but not ulcerative proctitis","volume":"11","author":"Horiuchi","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tips.2024.08.003_bb0150","first-page":"1185","article-title":"High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor \u03b1 antagonists","volume":"12","author":"Guo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.tips.2024.08.003_bb0155","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/ecco-jcc\/jjac014","article-title":"Markers of systemic inflammation in acute attacks of ulcerative colitis: what level of C-reactive protein constitutes severe colitis?","volume":"16","author":"Croft","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0160","article-title":"Clinical significance of the C-reactive protein-to-bilirubin ratio in patients with ulcerative colitis","volume":"10","author":"Huang","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.tips.2024.08.003_bb0165","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3390\/jcm11071881","article-title":"Measurement of serum IgG anti-integrin \u03b1v\u03b26 autoantibodies is a promising tool in the diagnosis of ulcerative colitis","volume":"11","author":"Rydell","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tips.2024.08.003_bb0170","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","article-title":"Anti-integrin alphavbeta6 autoantibodies are a novel biomarker that antedate ulcerative colitis","volume":"164","author":"Livanos","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2024.08.003_bb0175","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","article-title":"Identification of an anti-integrin \u03b1v\u03b26 autoantibody in patients with ulcerative colitis","volume":"160","author":"Kuwada","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2024.08.003_bb0180","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41591-022-01680-y","article-title":"Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity","volume":"28","author":"Uzzan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2024.08.003_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.dld.2023.06.024","article-title":"Diagnostic value of anti-integrin \u03b1v\u03b26 antibodies in ulcerative colitis","volume":"56","author":"Marafini","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.tips.2024.08.003_bb0190","article-title":"Proteomic analysis of potential targets for non-response to infliximab in patients with ulcerative colitis","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2024.08.003_bb0195","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/ibd\/izad241","article-title":"Exploring predictive biomarkers of relapse in ulcerative colitis: a proteomics approach","volume":"30","author":"Assadsangabi","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2024.08.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231155987","article-title":"Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease","volume":"16","author":"Magalhaes","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.tips.2024.08.003_bb0205","first-page":"9898","article-title":"Utility of a rapid assay for prostaglandin E-major urinary metabolite as a biomarker in pediatric ulcerative colitis","volume":"13","author":"Hagiwara","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.tips.2024.08.003_bb0210","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jgh.15782","article-title":"Prostaglandin E \u2013 major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase","volume":"37","author":"Sakurai","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0215","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s43588-021-00114-y","article-title":"The inflammatory bowel disease transcriptome and metatranscriptome meta-analysis (IBD TaMMA) framework","volume":"1","author":"Massimino","year":"2021","journal-title":"Nat. Comput. Sci."},{"key":"10.1016\/j.tips.2024.08.003_bb0220","first-page":"2520","article-title":"Serum miRNA signature diagnoses and discriminates murine colitis subtypes and predicts ulcerative colitis in humans","volume":"7","author":"Viennois","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.tips.2024.08.003_bb0225","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1021\/acs.analchem.5b00780","article-title":"Microelectrode miRNA sensors enabled by enzymeless electrochemical signal amplification","volume":"87","author":"Wang","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.tips.2024.08.003_bb0230","doi-asserted-by":"crossref","unstructured":"Masi, L. et al. MicroRNAs as innovative biomarkers for inflammatory bowel disease and prediction of colorectal cancer. Int. J. Mol. Sci. 23, 7991","DOI":"10.3390\/ijms23147991"},{"key":"10.1016\/j.tips.2024.08.003_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.658505","article-title":"Exosomes in intestinal inflammation","volume":"12","author":"Ayyar","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2024.08.003_bb0240","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0245","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213041119","article-title":"FXR mediates ILC-intrinsic responses to intestinal inflammation","volume":"119","author":"Fu","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.tips.2024.08.003_bb0250","doi-asserted-by":"crossref","unstructured":"Yang, Z.H. et al. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J. Gastroenterol. 27, 3609-3629","DOI":"10.3748\/wjg.v27.i24.3609"},{"key":"10.1016\/j.tips.2024.08.003_bb0255","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.gastha.2023.09.013","article-title":"Farnesoid X receptor agonists: a promising therapeutic strategy for gastrointestinal diseases","volume":"3","author":"Almeqdadi","year":"2024","journal-title":"Gastro Hep Adv."},{"key":"10.1016\/j.tips.2024.08.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13361","article-title":"The role of bile acid receptor TGR5 in regulating inflammatory signalling","volume":"99","author":"Ye","year":"2024","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.tips.2024.08.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2232143","article-title":"Gut microbiota-related bile acid metabolism-FXR\/TGR5 axis impacts the response to anti-\u03b14\u03b27-integrin therapy in humanized mice with colitis","volume":"15","author":"Han","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.tips.2024.08.003_bb0270","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct.Target. Ther."},{"key":"10.1016\/j.tips.2024.08.003_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.05.001","article-title":"Real-world experience with tofacitinib dose de-escalation in patients with moderate and severe ulcerative colitis","volume":"21","author":"Yu","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0280","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2024.08.003_bb0285","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0290","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2967\/jnumed.123.265649","article-title":"Detection of IL12\/23p40 via PET visualizes inflammatory bowel disease","volume":"64","author":"Rezazadeh","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2024.08.003_bb0295","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14712598.2024.2309300","article-title":"Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study","volume":"24","author":"Tursi","year":"2024","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.tips.2024.08.003_bb0300","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/00365521.2023.2278427","article-title":"Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a Spanish open-label cohort","volume":"59","author":"Iborra","year":"2024","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.tips.2024.08.003_bb0305","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ueg2.12492","article-title":"Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: a multicenter international study","volume":"12","author":"Allocca","year":"2024","journal-title":"United European Gastroenterol. J."},{"key":"10.1016\/j.tips.2024.08.003_bb0310","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.08.003_bb0315","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(23)00228-3","article-title":"The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis","volume":"401","author":"Atreya","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2024.08.003_bb0320","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.08.003_bb0325","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00011-023-01829-6","article-title":"Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Suilik","year":"2024","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.tips.2024.08.003_bb0330","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the true north open-label extension","volume":"18","author":"Danese","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0335","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2024.08.003_bb0340","first-page":"A142","article-title":"P207\u202feffects of fluconazole, gemfibrozil, and rifampin on the pharmacokinetics, safety, and tolerability of etrasimod","volume":"71","author":"Lee","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.tips.2024.08.003_bb0345","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0350","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjae007","article-title":"Achievement of clinical, endoscopic, and histological outcomes in patients with ulcerative colitis treated with etrasimod, and association with faecal calprotectin and C-reactive Protein: results from the Phase 2 OASIS trial","volume":"18","author":"Yarur","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0355","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221098899","article-title":"Vedolizumab blocks \u03b14\u03b27 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis","volume":"15","author":"Besendorf","year":"2022","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.tips.2024.08.003_bb0360","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial","volume":"7","author":"Peyrin-Biroulet","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111778","article-title":"Activation of free fatty acid receptors, FFAR1 and FFAR4, ameliorates ulcerative colitis by promote fatty acid metabolism and mediate macrophage polarization","volume":"130","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tips.2024.08.003_bb0370","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40259-021-00482-x","article-title":"A pharmacological batch of mongersen that downregulates Smad7 is effective as induction therapy in active Crohn\u2019s disease: a Phase II, open-label study","volume":"35","author":"Marafini","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.tips.2024.08.003_bb0375","doi-asserted-by":"crossref","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","article-title":"Mongersen (GED-0301) for active Crohn\u2019s disease: results of a Phase 3 study","volume":"115","author":"Sands","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.tips.2024.08.003_bb0380","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40291-022-00606-1","article-title":"Smad7 antisense oligonucleotide-based therapy in Crohn\u2019s disease: is it time to re-evaluate?","volume":"26","author":"Monteleone","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.tips.2024.08.003_bb0385","unstructured":"Clinicaltrials.gov (2024) Bethesda (MD). National Library of Medicine (US). [Internet]. 2024. Available from: https:\/\/www.clinicaltrials.gov"},{"key":"10.1016\/j.tips.2024.08.003_bb0390","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a Phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116430","article-title":"Huangqin decoction ameliorates ulcerative colitis by regulating fatty acid metabolism to mediate macrophage polarization via activating FFAR4-AMPK-PPAR\u03b1 pathway","volume":"311","author":"Li","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.tips.2024.08.003_bb0400","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3390\/nu13082716","article-title":"Activation of free fatty acid receptor 4 affects intestinal inflammation and improves colon permeability in mice","volume":"13","author":"Salaga","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.tips.2024.08.003_bb0405","doi-asserted-by":"crossref","first-page":"107","DOI":"10.12968\/jprp.2021.3.3.107","article-title":"Steroids in inflammatory bowel disease: a clinical review","volume":"3","author":"Hussenbux","year":"2021","journal-title":"J. Prescribing Pract."},{"key":"10.1016\/j.tips.2024.08.003_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.07.001","article-title":"Recent advances in the treatment of IBD: targets, mechanisms and related therapies","volume":"71-72","author":"Liu","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.tips.2024.08.003_bb0415","article-title":"The efficacy of currently licensed biologics for treatment of ulcerative colitis: a literature review","volume":"15","author":"Awan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.tips.2024.08.003_bb0420","first-page":"265","article-title":"Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease","volume":"18","author":"Choden","year":"2022","journal-title":"Gastroenterol. Hepatol. (N. Y.)"},{"key":"10.1016\/j.tips.2024.08.003_bb0425","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12876-023-02938-6","article-title":"Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis","volume":"23","author":"Chu","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.tips.2024.08.003_bb0430","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues","volume":"14","author":"Peyrin-Biroulet","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.tips.2024.08.003_bb0435","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s12876-022-02559-5","article-title":"Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease","volume":"22","author":"Goll","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.tips.2024.08.003_bb0440","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1753495X20919214","article-title":"Pregnancy and medications in inflammatory bowel disease","volume":"14","author":"Cao","year":"2021","journal-title":"Obstet. Med."},{"key":"10.1016\/j.tips.2024.08.003_bb0445","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-term safety and efficacy of risankizumab treatment in patients with Crohn\u2019s disease: results from the phase 2 open-label extension study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0450","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab232.039","article-title":"OP40 efficacy of risankizumab induction and maintenance therapy by baseline Crohn\u2019s disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"16","author":"Bossuyt","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0455","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized Phase 2 study of patients with Crohn\u2019s disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2024.08.003_bb0460","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/apt.16741","article-title":"Review article: the sphingosine 1 phosphate\/sphingosine 1 phosphate receptor axis \u2013 a unique therapeutic target in inflammatory bowel disease","volume":"55","author":"Wang","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2024.08.003_bb0465","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the Phase 2 GALAXI-1 Study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2024.08.003_bb0470","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2024.08.003_bb0475","article-title":"OP24 Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 U-ACHIEVE study","volume":"15","author":"Danese","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0480","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab075.022","article-title":"OP23 Efficacy and safety of upadacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: results from phase 3 U-ACCOMPLISH study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0485","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab075.032","article-title":"OP33 oral ritlecitinib and brepocitinib in patients with moderate to severe active ulcerative colitis, data from the VIBRATO umbrella study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0490","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","article-title":"Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0495","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.tips.2024.08.003_bb0500","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2468-1253(21)00295-8","article-title":"Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2024.08.003_bb0505","doi-asserted-by":"crossref","unstructured":"Henn, M.R. et al. A Phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis. Gastroenterology 160, 115-27.e30","DOI":"10.1053\/j.gastro.2020.07.048"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614724001652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614724001652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:08:25Z","timestamp":1727953705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614724001652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":101,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0165614724001652"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2024.08.003","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}